A class of multi-sample nonparametric tests for panel count data

Medical follow-up study, Nonparametric comparison, Panel count data, Point processes,

A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. thyroid cancer cooperative group

Using survival from all causes of death as an endpoint, the prognostic significance of age, sex, cell type, clinical extent of tumor, lymph node status and number of metastatic sites (all recorded at the time of diagnosis) was studied in a set of data for 500 patients with histologically confirmed thyroid carcinoma. Each of these variables was found to have prognostic significance when examined singly, but some were strongly correlated with others. A simple prognostic index based on a multivariate analysis using a Weibull survival model is presented which allows one to assess the joint effects of the prognostic variables and indentifies patients with markedly different survival probabilities. The index may be used to predict survival for individual patients as an adjustment variable in treatment comparisons, or as a stratification variable in designing prospective randomized trials of treatment. © 1979.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Results of a E.O.R.T.C. randomized trial of cyclophosphamide and radiotherapy in inoperable lung cancer: Prognostic factors and treatment results

A randomized cooperative clinical trial has been conducted in inoperable carcinoma of the lung. One hundred and eighty-seven patients under age 72 of both sexes of all cell types were admitted provided they had had no previous surgery, chemotherapy or radiotherapy with the exception that patients having received less than 2g of cyclophosphamide or less than 2 weeks of chemotherapy of any kind could be included. Treatment was assigned by randomization, stratified by institution and cell type, to one of the following treatments: (1) continuous radiotherapy (6000 rad at the rate of 1000 rad per week), (2) split-course radiotherapy (3 series of 2000 rad each administered in three 2-week periods separated by 8-week intervals), (3) continuous radiotherapy plus cyclophosphamide, (4) split-course radiotherapy plus cyclophosphamide. Cyclophosphamide was given at the dose of 20 mg/kg i.v. or i.m. every 15 days starting 15 days after the completion of continuous radiotherapy or 15 days after the first course of radiotherapy for those receiving the split-dose schedule. No statistically significant differences in survival were seen between treatment groups. © 1978.SCOPUS: ar.jinfo:eu-repo/semantics/publishe